Liver biopsy is a useful diagnostic procedure for which a variety of techniques is in use. A recently introduced innovation is the sheathed needle (Tru-Cut), employed also for breast, kidney, and prostate biopsy. This needle is claimed to yield a better success rate in cirrhosis, ' though The patients had a screen of blood tests before biopsy and were required to have a haemoglobin greater than 10 g/dl, platelet count greater than 100 x 109/l, and a prothrombin time not more than 2 seconds greater than the control. The blood group was determined and serum was saved for possible cross-matching. After biopsy patients were kept lying in bed until the following morning. Pulse and blood pressure were measured four times in the first hour and thereafter hourly until the patient fell asleep at night.
If patients complained of local or shoulder-tip pain an injection of pentazocine 30 mg was given. A chest radiograph was performed on the day after biopsy to exclude pneumothorax.
Results
The clinical diagnoses necessitating liver biopsy are given in Table 1 The success of the liver biopsy was assessed in this study by the volume of the largest core obtained, calculated from its length measured immediately after the procedure. This method avoided delays in fixation. It also had the advantage over weighing that it did not depend on density, which will be different in pathological conditions such as fatty liver or fibrosis. Fragmentation of the sample was confirmed as a commoner feature of suction biopsy, but even so a satisfactory sample was obtained with the Menghini needle in all but one case.
The diameter of the needle used was determined by the standard size of the Tru-Cut needle. Although there is some suggestion that smaller diameter needles may be safer,7-9 this has not been proved. Since more satisfactory samples after a single attempt may be expected with larger needles, and the complication rate is strongly correlated with the number of attempts,6 a carefully designed prospective trial would be required to provide a satisfactory answer to the question of safety.
Pain occurred more frequently in our series than in others reported. In one study, 12 out of 140 patients had pain,4 and in another 45 out of 1000.6 Pain is a highly subjective clinical phenomenon, and the incidence in retrospective series may not provide an accurate estimate of discomfort experienced. Also, in our series two patients developed more severe complications which were both recognised hazards of liver biopsy and did not clearly relate to the type of needle used.
The failure of a second biopsy to yield tissue in four of our patients probably reflected the restriction of the procedure to two punctures. Even with up to 11 attempts a failure rate of 1-9 % has been recorded. 6 We could show no advantage for the Tru-Cut needle over the Menghini needle when comparable needle diameter and depth of liver penetration were employed. The cost of the disposable Tru-Cut needle was (and remains) much more than that of the repeatedly reusable Menghini needle: £4.16 and £1-62 respectively for the needles used in this study. Even if the Menghini needle was discarded after a single use, and allowing for the cost of syringe and saline, the Tru-Cut needle still costs twice as much. The greater expense cannot be justified on diagnostic grounds.
It had been hoped that, as from January 1980, references in all papers would be given in the numbered 'Vancouver' style. However, in the interests of contributors who had submitted manuscripts before the general directive was published, there will be some papers with the Harvard style of references in the first two or three issues of 1980. This should not be construed as an encouragement to authors to continue to submit papers in the old style.-Ed.
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